Total | Without complication | With complication | ||
---|---|---|---|---|
Variable* | n = 95 (%) | n = 54 (%) | n = 41 (%) | p-value |
Age, years (IQR) | 57 (48 ~ 67) | 57 (49 ~ 67) | 57 (46 ~ 66) | 0.974 |
Age ≥ 60 years | 41 (43) | 24 (44) | 17 (42) | 0.771 |
Male | 52 (55) | 26 (48) | 26 (63) | 0.139 |
mFI-5 score | 0.366 | |||
< 2 | 60 (63) | 32 (34) | 28 (29) | |
≥ 2 | 35 (37) | 22 (23) | 13 (14) | |
Preoperative GCS (IQR) | 15 (15 ~ 15) | 15 (15 ~ 15) | 15 (13 ~ 15) | - |
Preoperative seizure | 6 (6) | 4 (7) | 2 (5) | 0.616 |
ASA score > 2 | 53 (56) | 24 (44) | 29 (71) | 0.011 |
Preoperative laboratory data (IQR) | ||||
WBC (K/µL) | 9.0 (7.0 ~ 12.0) | 8.5 (7.0 ~ 10.0) | 9.0 (7.5 ~ 15.5) | 0.059 |
Hct (%) | 41.0 (37.0 ~ 44.0) | 41.0 (37.0 ~ 44.0) | 41.0 (36.5 ~ 44.0) | 0.884 |
Hb (g/dL) | 14.0 (12.0 ~ 15.0) | 14.0 (12.0 ~ 15.0) | 14.0 (12.0 ~ 15.0) | 0.940 |
Platelet (K/µL) | 218 (186 ~ 281) | 231 (190 ~ 286) | 209 (183 ~ 275) | 0.249 |
Cr (mg/dL) | 1.0 (1.0 ~ 1.0) | 1.0 (1.0 ~ 1.0) | 1.0 (1.0 ~ 1.0) | 0.808 |
BUN (mg/dL) | 15 (12 ~ 19) | 14 (12 ~ 18) | 15 (12 ~ 22) | 0.190 |
eGFR (ml/min) (SD) | 84.9 ± 23.3 | 86.7 ± 21.0 | 82.7 ± 26.1 | 0.409 |
Na (mmol/L) | 141 (138 ~ 142) | 141 (138 ~ 142) | 140 (138 ~ 142) | 0.533 |
K (mmol/L) | 4.0 (4.0 ~ 4.0) | 4.0 (4.0 ~ 4.0) | 4.0 (4.0 ~ 4.0) | 0.140 |
GPT (U/L) | 19 (15 ~ 33) | 19 (14 ~ 31) | 21 (16 ~ 40) | 0.614 |
Pathological type | 0.108 | |||
Glioblastomas | 70 (73.7) | 41 (43.2) | 29 (30.5) | |
Anaplastic astrocytomas | 10 (10.5) | 3 (3.2) | 7 (7.4) | |
Anaplastic oligodendrogliomas | 8 (8.4) | 7 (7.4) | 1 (1.1) | |
Others | 7 (7.4) | 4 (4.2) | 3 (3.2) | |
WHO grade | 0.972 | |||
3 | 23 (24) | 13 (14) | 10 (11) | |
4 | 72 (76) | 41 (43) | 31 (33) | |
Duration of anesthesia (h) (IQR) | 11.0 (9.0 ~ 13.0) | 10.0 (8.0 ~ 13.0) | 12.0 (9.5 ~ 14.5) | 0.221 |
Tumor volume (cm3) (SD) | 6.7 ± 1.7 | 6.6 ± 1.6 | 6.7 ± 1.7 | 0.642 |